Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2835PDF: 847HTML: 6518Untitled: 226Untitled: 189Untitled: 203Untitled: 210 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1233PDF: 756HTML: 313 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1181PDF: 752HTML: 1348Figure 1: 186Figure 2: 188 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2579PDF: 798HTML: 5212 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3581PDF: 885HTML: 6710 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1719PDF: 1163HTML: 245 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1610PDF: 806HTML: 165 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3248PDF: 1089HTML: 434 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2902PDF: 1585HTML: 233 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3882PDF: 755HTML: 1848 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2079PDF: 1517HTML: 284 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
995PDF: 984Suppl. Files: 635HTML: 126 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7431PDF: 2420HTML: 1732Table 1.: 208Table 2.: 217Table 3.: 201Table 4.: 200 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
805PDF: 420HTML: 285 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2189PDF: 1486HTML: 266 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2575PDF: 737HTML: 2297 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1376PDF: 1306HTML: 99 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1523PDF: 941HTML: 222 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1173PDF: 830HTML: 3361 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1457PDF: 1058HTML: 216 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2134PDF: 1322HTML: 3501 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1240PDF: 985HTML: 210 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
704PDF: 388Suppl. Files: 120HTML: 112 -
Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission
1658PDF: 746HTML: 246







